Carmell Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $17 | $20 | $12 | $0 |
Gross Profit | 16 | 15 | 12 | -57 |
EBITDA | -2,828 | -3,236 | -3,470 | |
EBIT | -2,871 | -3,295 | -3,528 | |
Net Income | -914 | -2,878 | -3,304 | -4,805 |
Net Change In Cash | 17 | 20 | 12 | 0 |
Free Cash Flow | -772 | 2,452 | -1,138 | -1,075 |
Cash | 157 | 1,137 | 2,198 | 892 |
Basic Shares | 28,970 | 20,905 | 20,735 | 22,915 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $50 | $0 | $0 | $0 |
Gross Profit | 43 | -124 | -242 | |
EBITDA | -15,191 | -5,254 | -1,660 | |
EBIT | -15,315 | -5,496 | -1,902 | |
Net Income | -10,368 | -15,445 | -9,051 | -6,478 |
Net Change In Cash | 50 | 0 | 0 | 0 |
Free Cash Flow | -4,388 | -8,378 | -3,435 | -1,184 |
Cash | 157 | 2,912 | 128 | 12 |
Basic Shares | 28,970 | 11,021 | 19,769 | 19,769 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.15 |
2024-03-31 | -$0.14 |
2023-09-30 | -$0.61 |
2023-06-30 | $0.01 |
